
Peptide T
CAS No. 106362-32-7
Peptide T( —— )
Catalog No. M30483 CAS No. 106362-32-7
Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 162 | Get Quote |
![]() ![]() |
10MG | 279 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePeptide T
-
NoteResearch use only, not for human use.
-
Brief DescriptionPeptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action.
-
DescriptionPeptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action(In Vitro):Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4. Peptide T at 10-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10-9 M concentration significantly inhibits IFN-g production by PBMC.(In Vivo):Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE.
-
In VitroPeptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4. Peptide T at 10-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10-9 M concentration significantly inhibits IFN-g production by PBMC.
-
In VivoPeptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE.
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorCD4, HIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number106362-32-7
-
Formula Weight857.86
-
Molecular FormulaC35H55N9O16
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 100 mg/mL (116.57 mM)
-
SMILES——
-
Chemical NameSequence:Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751.
molnova catalog



related products
-
RN-18
RN-18 is a small molecule that antagonizes HIV-1 Vif function and inhibits HIV-1 replication only in the presence of A3G.
-
1E7-03
1E7-03 is a small molecule targeting the RVxF interacting site on PP1, inhibits HIV-1, Ebolavirus (EBOV), and Venezuelan equine encephalitis virus (VEEV, EC50=0.6 uM).
-
Dolutegravir
Dolutegravir (GSK1349572) is a potent, next-generation HIV integrase (IN) inhibitor, inhibits HIV-1 integrase-catalyzed strand transfer with IC50 of 2.7 nM.